Welcome to our dedicated page for YIELD10 BISCIENCE NEW news (Ticker: YTEN), a resource for investors and traders seeking the latest updates and insights on YIELD10 BISCIENCE NEW stock.
Yield10 Bioscience, Inc. (Nasdaq: YTEN) is a pioneering agricultural bioscience company focusing on the development of cutting-edge technologies for significant improvements in crop yield within the United States and Canada. Founded in 1992 and headquartered in Woburn, Massachusetts, Yield10 leverages advanced genetic engineering to develop high-value traits in seeds, targeting the agriculture and food industries through its Trait Factory. The company has a dedicated oilseed development center in Saskatchewan, Canada.
The core mission of Yield10 is to harness the genetic potential of the oilseed Camelina sativa ('Camelina') for the production of sustainable seed products. These products include feedstock oils for renewable diesel and sustainable aviation biofuels, omega-3 (EPA and DHA+EPA) oils for pharmaceutical, nutraceutical, and aquafeed applications, and future plans for PHA biomaterials to be used as biodegradable bioplastics.
Yield10’s research initiatives are bolstered by strategic partnerships with industry giants such as Bayer AG for soybean traits, Forage Genetics International, LLC for forage sorghum traits, J. R. Simplot Company for potato traits, and GDM Seeds Inc. for evaluating yield traits in soybeans. These collaborations underscore the company’s commitment to innovation and broadening the impact of its technologies.
Significant recent milestones include the development and successful field testing of proprietary winter Camelina varieties engineered for herbicide tolerance. These varieties showed promising results in tolerating glufosinate and Group 2 herbicides, which are crucial for managing weeds and ensuring high yield in crop rotations across North America. This advancement is expected to facilitate the large-scale adoption of Camelina for biofuel and omega-3 oil markets, with the potential for commercial production as early as 2025.
Regulatory progress has been a key aspect of Yield10’s strategy, with USDA-APHIS determining that its genetically engineered Camelina traits are not subject to certain regulations, allowing for expanded planting and breeding in the United States. Additionally, the Canadian Food Inspection Agency has cleared Yield10's E3902 Camelina, which features enhanced oil production and a lighter seed coat.
Yield10 continues to build on its commercial and regulatory achievements, exemplified by the recent agreement with Vision Bioenergy Oilseeds to license Camelina varieties for biofuel feedstock production. This collaboration aims to support the growing demand for low-carbon intensity feedstock oil, aligning with global decarbonization goals.
For more detailed information about Yield10 Bioscience and its innovative endeavors, visit www.yield10bio.com or follow the company on X (formerly Twitter), Facebook, and LinkedIn.
Yield10 Bioscience (Nasdaq:YTEN) has announced significant advancements in utilizing Camelina for producing PHA bioplastics directly in seeds. Following successful field tests in 2021, the company plans to scale up production to acre-scale in 2022, focusing on both spring and winter Camelina lines. Yield10 aims to improve PHA levels in seeds to 10-20 percent, which opens new market opportunities for farmers. The company highlights the potential of Camelina to address the global plastic waste crisis with biodegradable materials.
Yield10 Bioscience (Nasdaq:YTEN) has announced a scale-up of its Camelina line E3902 seed production aimed at providing low-carbon feedstock oil for the renewable diesel market. In 2022, the company plans to advance field testing of herbicide-tolerant Camelina lines as part of its commercialization efforts. The E3902 line has demonstrated a 5% increase in seed oil content. Demand for renewable diesel is rising in the U.S. and Canada, driven by a shift toward low-carbon fuels. Yield10 aims to position Camelina as a competitive feedstock in this expanding market.
Yield10 Bioscience, Inc. (Nasdaq:YTEN) announced it will report its Q4 and full year 2021 financial results on March 9, 2022. The company will hold a conference call at 4:30 p.m. ET to discuss the financial outcomes and provide a corporate update, followed by a Q&A session. Interested parties can access the call via phone or live webcast. Additionally, a replay will be available for two weeks post-call. Yield10 focuses on developing improved Camelina varieties for agricultural applications and aims to commercialize high-value seed products.
Yield10 Bioscience (Nasdaq: YTEN) reported promising results from its 2021 field tests for oil content traits C3020 in Camelina and C3007 in canola. C3020 demonstrated a seed oil content increase of up to 9%, while C3007 achieved around 5%. Further testing is scheduled for spring 2022. The company is positioning itself to meet the rising demand for renewable diesel feedstocks, capitalizing on the projected growth in the vegetable oil market. Their innovative approach may enhance the economic value of oilseed crops.
Yield10 Bioscience announced a favorable ruling from Argentina's CONABIA, confirming that three CRISPR genome-edited Camelina lines are similar to conventional varieties. This classification allows Yield10 to market these lines without pre-market authorizations. The E3902 line has demonstrated a 5% increase in seed oil content compared to controls. This decision streamlines the company's operations in Argentina, enhancing its ability to scale up seed production aimed at high-value markets, particularly in oil and meal production targeting aquaculture.
Yield10 Bioscience has appointed Darren Greenfield as the new Senior Director of Seed Operations, effective immediately. With over 25 years of experience in the agriculture sector, Greenfield will focus on scaling up Camelina seed production. His prior roles include work with BASF and Dow Agrosciences. Yield10 aims to enhance its seed products pipeline, targeting biofuel feedstock demands and planning to launch new varieties, including omega-3 nutritional oils. This leadership change is expected to strengthen operations and drive growth in the commercial market.
Yield10 Bioscience, Inc. (Nasdaq: YTEN) announced that President and CEO Oliver Peoples, Ph.D. will present at the H.C. Wainwright Bioconnect Investment Conference, held virtually from January 10-13, 2022. The presentation will be available starting at 7:00 a.m. ET on January 10. Additionally, Yield10 management will participate in one-on-one meetings with registered investors. The company focuses on developing enhanced Camelina varieties and high-value genetic traits for the agriculture industry.
Yield10 Bioscience (Nasdaq: YTEN) has announced its participation in the Benzinga Global Small Cap Conference on December 9, 2021. President and CEO Oliver Peoples, Ph.D. will present at 10:30 AM EST, followed by one-on-one meetings with registered investors. An archived replay of the presentation will be accessible via the conference website. Yield10 focuses on agricultural bioscience, utilizing its Trait Factory platform to develop superior Camelina varieties and high-value genetic traits for various crops.
Yield10 Bioscience announced Dr. Kristi Snell's presentation at the Canola Week 2021 Conference from November 30 to December 2, 2021. She will discuss "Genome editing to increase seed oil in Camelina" using CRISPR technology during the session on December 2. The company is developing novel traits to boost seed oil content in oilseed crops, specifically focusing on the E3902 line created through genome editing. This initiative aligns with the rising demand for oil feedstock for renewable diesel in North America.
Yield10 Bioscience (Nasdaq:YTEN) announced its financial results for Q3 2021, reporting a net loss of $2.4 million, or $0.49 per share, compared to a net loss of $2.2 million, or $0.87 per share, in Q3 2020. The company has $18.5 million in unrestricted cash and investments, a decrease from $20.6 million in Q2 2021. Yield10’s operational progress includes successful PHA bioplastic seed scale-up and ongoing trials for its winter Camelina varieties, targeting biodiesel market opportunities. The company expects to fund operations into Q2 2023, pending additional financing.
FAQ
What is the current stock price of YIELD10 BISCIENCE NEW (YTEN)?
What is the market cap of YIELD10 BISCIENCE NEW (YTEN)?
What does Yield10 Bioscience do?
Where is Yield10 Bioscience headquartered?
What are some recent achievements of Yield10 Bioscience?
Who are Yield10 Bioscience’s key partners?
What is Camelina sativa?
What is the significance of Yield10’s herbicide tolerance tests?
What are Yield10’s future plans for Camelina?
What regulatory milestones has Yield10 achieved?
How is Yield10 addressing the demand for omega-3 oils?
Where can I find more information about Yield10 Bioscience?
